Dataset Information

Rosiglitazone promotes ENaC-mediated alveolar fluid clearance in acute lung injury through the PPAR?/SGK1 signaling pathway.

ABSTRACT:

Background

Pulmonary edema is one of the pathological characteristics of acute respiratory distress syndrome (ARDS). The epithelial sodium channel (ENaC) is thought to be the rate-limiting factor for alveolar fluid clearance (AFC) during pulmonary edema. The peroxisome proliferator-activated receptor ? (PPAR?) agonist rosiglitazone was shown to stimulate ENaC-mediated salt absorption in the kidney. However, its role in the lung remains unclear. Here, we investigated the role of the PPAR? agonist in the lung to find out whether it can regulate AFC during acute lung injury (ALI). We also attempted to elucidate the mechanism for this.

Methods

Our ALI model was established through intratracheal instillation of lipopolysaccharide (LPS) in C57BL/6?J mice. The mice were randomly divided into 4 groups of 10. The control group underwent a sham operation and received an equal quantity of saline. The three experimental groups underwent intratracheal instillation of 5?mg/kg LPS, followed by intraperitoneal injection of 4?mg/kg rosiglitazone, 4?mg/kg rosiglitazone plus 1?mg/kg GW9662, or only equal quantity of saline. The histological morphology of the lung, the levels of TNF-? and IL-1? in the bronchoalveolar lavage fluid (BALF), the level of AFC, and the expressions of ?ENaC and serum and glucocorticoid-induced kinase-1 (SGK1) were determined. Type 2 alveolar (AT II) cells were incubated with rosiglitazone (15??M) with or without GW9662 (10??M). The expressions of ?ENaC and SGK1 were determined 24?h later.

Results

A mouse model of ALI was successfully established. Rosiglitazone significantly ameliorated the lung injury, decreasing the TNF-? and IL-1? levels in the BALF, enhancing AFC, and promoting the expressions of ?ENaC and SGK1 in ALI mice, which were abolished by the specific PPAR? blocker GW9662. In vitro, rosiglitazone increased the expressions of ?ENaC and SGK1. This increase was prevented by GW9662.

Conclusions

Rosiglitazone ameliorated the lung injury and promoted ENaC-mediated AFC via a PPAR?/SGK1-dependent signaling pathway, alleviating pulmonary edema in a mouse model of ALI.

SUBMITTER: He J

PROVIDER: S-EPMC6540532 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Rosiglitazone promotes ENaC-mediated alveolar fluid clearance in acute lung injury through the PPARγ/SGK1 signaling pathway.

He Jing J Qi Di D Tang Xu-Mao XM Deng Wang W Deng Xin-Yu XY Zhao Yan Y Wang Dao-Xin DX

Cellular & molecular biology letters 20190528

<h4>Background</h4>Pulmonary edema is one of the pathological characteristics of acute respiratory distress syndrome (ARDS). The epithelial sodium channel (ENaC) is thought to be the rate-limiting factor for alveolar fluid clearance (AFC) during pulmonary edema. The peroxisome proliferator-activated receptor γ (PPARγ) agonist rosiglitazone was shown to stimulate ENaC-mediated salt absorption in the kidney. However, its role in the lung remains unclear. Here, we investigated the role of the PPARγ ...[more]

PMID: 31160894

Similar Datasets

Project description:Rationale: It has been reported that peroxisome proliferator activated receptor γ (PPARγ) level decreases significantly in the brains of Alzheimer's disease (AD) patients and mice models, while the mechanism is unclear. This study aims to unravel the mechanism that amyloid β (Aβ) decreases PPARγ and attempted to discover lead compound that preserves PPARγ. Methods: In APP/PS1 transgenic mice and Aβ treated microglia, the interaction between HSP90 and PPARγ were analyzed by western blot. Using a PPRE (PPARγ responsive element) containing reporter cell line, compounds that activate PPARγ activity were identified. After genetic ablation or pharmacological inhibition of potential target pathways, the target of jujuboside A (JuA) was discovered through Axl/HSP90β. After oral administration or intrathecal injection, the anti-AD activity of JuA was evaluated by Morris water maze (MWM) test and object recognition test. Soluble Aβ42 levels and plaque numbers after JuA treatment were detected by thioflavin S staining, and the activation of microglia was assayed by immunofluorescence staining against Iba-1. Results: We found that Aβ stress decreased heat shock protein 90 β (HSP90β), subsequently reduced the abundance of PPARγ, and down-regulated Aβ clearance-related genes in BV2 cells and primary microglia. We identified that JuA stimulated the expression of HSP90β, strengthened the interaction between HSP90β and PPARγ, preserved PPARγ levels, and thus effectively promoted the clearance of Aβ42. We demonstrated that JuA increased HSP90β expression through Axl/ERK pathway. JuA significantly ameliorated cognitive deficiency in APP/PS1 transgenic mice, meanwhile, JuA significantly reduced the soluble Aβ42 levels and plaque numbers in the brain. Notably, the therapeutic effects of JuA were dampened by R428, an Axl inhibitor. Conclusions: This study suggests that the up-regulation of HSP90β by JuA through Axl is a potential therapeutic strategy to facilitate Aβ42 clearance and ameliorate cognitive deficiency in AD.